Επιστημονικές Ενημερώσεις Φεβρουάριος 2025 – Diabetes Blog – Σπύρος Καραμαγκιώλης, Διαβητολόγος

Diabetologia

Prediabetes is associated with elevated risk of clinical outcomes even without progression to diabetes Open Access
Citation: Rooney, M.R., Wallace, A.S., Echouffo Tcheugui, J.B. et al. Prediabetes is associated with elevated risk of clinical outcomes even without progression to diabetes. Diabetologia 68, 357–366 (2025). https://doi.org/10.1007/s00125-024-06315-0

Abstract Aims/hypothesis: Prediabetes (HbA_1c 39–47 mmol/mol [5.7–6.4%] or fasting glucose 5.6–6.9 mmol/l) is associated with elevated risks of microvascular and macrovascular complications. It is unknown to what extent these risks in prediabetes remain after accounting for progression to diabetes. Methods: (…) Conclusions/interpretation: Progression to diabetes explained less than one-quarter of the risks of clinical outcomes associated with prediabetes. Prediabetes contributes to the risk of clinical outcomes even without progression to diabetes. Διαβάστε τη δημοσίευση

Evidence on the effectiveness and equity of population-based policies to reduce the burden of type 2 diabetes: a narrative review Open Access
Citation: Mackenbach, J.D., Stuber, J.M. & Beulens, J.W.J. Evidence on the effectiveness and equity of population-based policies to reduce the burden of type 2 diabetes: a narrative review. Diabetologia 68, 281–294 (2025). https://doi.org/10.1007/s00125-024-06330-1

Abstract There is increasing evidence for the effectiveness of population-based policies to reduce the burden of type 2 diabetes. Yet, there are concerns about the equity effects of some policies, whereby socioeconomically disadvantaged populations are not reached or are adversely affected. There is a lack of knowledge on the effectiveness and equity of policies that are both population based (i.e. targeting both at-risk and low-risk populations) and low agency (i.e. not requiring personal resources to benefit from the policy). (…) Διαβάστε τη δημοσίευση

Diabetes Care

Homepage

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials Free
Citation: Hon Jen Wong, Bryan Sim, Yao Hao Teo, Yao Neng Teo, Mark Y. Chan, Leonard L.L. Yeo, Pei Chia Eng, Benjamin Y.Q. Tan, Naveed Sattar, Mayank Dalakoti, Ching-Hui Sia; Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care 22 January 2025; 48 (2): 292–300.https://doi.org/10.2337/dc24-1678

Abstract Objective: To provide an updated synthesis on effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on weight, BMI, and waist circumference incorporating newer randomized controlled trials (RCTs), particularly in individuals with overweight or obesity. Research design and methods: (…) Conclusions: GLP-1 RAs demonstrated significant weight, BMI, and waist circumference reduction benefits in this meta-analysis. Διαβάστε τη δημοσίευση

Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial Free
Citation: Patrizia Pasanisi, Andreina Oliverio, Ivan Baldassari, Eleonora Bruno, Elisabetta Venturelli, Manuela Bellegotti, Giuliana Gargano, Daniele Morelli, Antonio Bognanni, Marta Rigoni, Paola Muti, Franco Berrino; Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial. Diabetes Care 22 January 2025; 48 (2): 265–272. https://doi.org/10.2337/dc24-1597

Abstract Objective: The Metformin and Dietary Restriction to Prevent Age-Related Morbid Events in People With Metabolic Syndrome (MeMeMe) trial tested whether 1,700 mg/day metformin (MET) with or without a Mediterranean diet (MedDiet) intervention could reduce the cumulative incidence of major noncommunicable diseases in people with metabolic syndrome. (…) Conclusions: The use of 1,700 mg/day MET is effective to prevent diabetes in people selected on the basis of metabolic syndrome. Διαβάστε τη δημοσίευση